Early detection of glioblastoma could dramatically improve outcomes for patients facing this devastating cancer, where median survival remains stuck at just 15 months despite aggressive treatment. The challenge has been identifying brain tumors before symptoms appear, when current imaging and biopsy methods often miss early-stage disease. Microfluidic technology represents a potential breakthrough by transforming how clinicians detect circulating tumor biomarkers in blood samples. These microscale devices can concentrate and analyze minute quantities of glioblastoma-specific exosomes, DNA fragments, and proteins that traditional blood tests cannot reliably detect. The platforms require only tiny sample volumes while enabling real-time monitoring of tumor progression. This technological approach addresses a critical gap in neuro-oncology, where the blood-brain barrier has historically made liquid biopsies less effective than for other cancers. The ability to repeatedly sample blood rather than requiring invasive brain tissue biopsies could enable earlier intervention and personalized treatment adjustments based on molecular tumor evolution. While promising, microfluidic biosensors for brain cancer remain largely in development phases. The technology must demonstrate consistent sensitivity across diverse patient populations and tumor subtypes before clinical adoption. Current glioblastoma biomarkers in blood circulation are present at extremely low concentrations, requiring continued refinement of detection thresholds. Success would represent a paradigm shift from reactive to predictive brain cancer care, potentially identifying tumors months before conventional diagnosis.